News story

Latest topics referred to NICE: November 2011

This news article was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government

Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence** **(NICE) …

Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence** **(NICE) in November, to begin the process of developing guidance for each topic.

Technology appraisals

**These are the technology appraisals that have been referred to NICE.

  • To appraise the clinical and cost effectiveness of denosumab within its licensed indication for prolonging bone metastasis-free survival in castrate-resistant prostate cancer.
  • To appraise the clinical and cost effectiveness of lapatinib in combination with paclitaxel within its licensed indication for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor.
  • To appraise the clinical and cost effectiveness of vorinostat in combination with bortezomib (velcade) within its licensed indication for the treatment of multiple myeloma in people who have received at least one prior therapy.
  • To appraise the clinical and cost effectiveness of bosutinib within its licensed indication for the first-line treatment of chronic myeloid leukaemia.
  • To appraise the clinical and cost effectiveness of abiraterone acetate in combination with prednisolone (Prelone) within its licensed indication for the treatment of metastatic, castrate-resistant prostate cancer in people who have not been previously treated with chemotherapy.
  • To appraise the clinical and cost effectiveness of apixaban within its licensed indication for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation with one or more risk factor for stroke or systemic embolism.
  • To appraise the clinical and cost effectiveness of rifaximin within its licensed indication for the maintenance treatment of hepatic encephalopathy.
  • To appraise the clinical and cost effectiveness of crizotinib within its licensed indication for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene.
  • To appraise the clinical and cost effectiveness of romidepsin within its licensed indication for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Find out more about NICE technology appraisals on the NICE website.

Quality standards

The following quality standard was referred to NICE.

  • Hypertension

Read about NICE quality standards on the NICE website.

About NICE referrals

NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.

Department of Health ministers refer topics to NICE and NICE schedules these topics into its work programme, to begin the process of developing guidance for each topic.

Depending on the type of guidance and its complexity, this can take between 6 months and 2 years.

NICE guidance includes technology appraisals, clinical guidelines, public health guidelines and quality standards.

Find out more about NICE guidance on the NICE website.